Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$1.64 +2.8%	$1.44	$0.87 ▼ $6.78	$163.48M	0.74	825,269 shs	143,663 shs
FDMT 4D Molecular Therapeutics	$4.21 -0.3%	$3.96	$2.24 ▼ $19.69	$195.28M	2.81	754,789 shs	88,910 shs
HLVX HilleVax	$2.04 -1.0%	$1.96	$1.34 ▼ $2.17	$102.29M	0.76	283,524 shs	33,255 shs
NVAX Novavax	$7.03 +0.4%	$6.88	$5.01 ▼ $17.81	$1.14B	2.69	6.13 million shs	920,926 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	-1.24%	+8.16%	+63.34%	-72.73%
FDMT 4D Molecular Therapeutics	0.00%	-1.40%	+2.18%	+37.01%	-70.69%
HLVX HilleVax	0.00%	-1.44%	+10.75%	+24.10%	+16.38%
NVAX Novavax	0.00%	+2.34%	+9.20%	+16.47%	-49.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALEC Alector	3.5697 of 5 stars	3.1	2.0	4.5	1.1	2.5	0.0
FDMT 4D Molecular Therapeutics	2.2713 of 5 stars	3.3	3.0	0.0	1.4	1.7	0.6
HLVX HilleVax	1.7202 of 5 stars	1.0	5.0	0.0	0.0	3.3	1.3
NVAX Novavax	4.4163 of 5 stars	3.1	1.0	4.7	2.1	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.14	Hold	$4.00	144.65% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	602.70% Upside
HLVX HilleVax	2.00	Hold	$2.00	-1.96% Downside
NVAX Novavax	2.29	Hold	$17.00	141.99% Upside

Current Analyst Ratings Breakdown

Latest HLVX, FDMT, ALEC, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	ALEC Alector	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$100.56M	1.63	N/A	N/A	$1.29 per share	1.27
FDMT 4D Molecular Therapeutics	$40K	4,871.60	N/A	N/A	$11.05 per share	0.38
HLVX HilleVax	N/A	N/A	N/A	N/A	$3.10 per share	N/A
NVAX Novavax	$682.16M	1.67	N/A	N/A	($3.89) per share	-1.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.26	N/A	N/A	N/A	-139.74%	-100.58%	-25.15%	8/6/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/6/2025 (Estimated)
HLVX HilleVax	-$147.27M	-$2.15	N/A	N/A	N/A	N/A	-51.86%	-41.45%	8/14/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.65	2.65	87.81	0.06	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)

Latest HLVX, FDMT, ALEC, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.6922	N/A	N/A	N/A	$0.52 million	N/A
8/14/2025	Q2 2025	HLVX HilleVax	-$0.14	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	NVAX Novavax	-$0.12	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	ALEC Alector	-$0.45	N/A	N/A	N/A	$2.76 million	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
5/8/2025	Q1 2025	HLVX HilleVax	-$0.37	-$0.12	+$0.25	-$0.12	N/A	N/A
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
HLVX HilleVax	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.10	3.34	3.34
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
HLVX HilleVax	N/A	25.32	25.32
NVAX Novavax	N/A	2.06	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
FDMT 4D Molecular Therapeutics	99.27%
HLVX HilleVax	86.42%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.10%
FDMT 4D Molecular Therapeutics	9.60%
HLVX HilleVax	24.90%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	99.99 million	90.89 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
HLVX HilleVax	20	50.14 million	37.66 million	Not Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable

HLVX, FDMT, ALEC, and NVAX Headlines

Recent News About These Companies

Hussman Strategic Advisors Inc. Grows Stock Position in Novavax, Inc. (NASDAQ:NVAX)

July 19 at 8:01 AM | marketbeat.com

Novavax Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 17, 2025 | marketwatch.com

Novavax (NVAX) Rises Higher Than Market: Key Facts

July 15, 2025 | msn.com

45,000 Shares in Novavax, Inc. (NASDAQ:NVAX) Purchased by DekaBank Deutsche Girozentrale

July 15, 2025 | marketbeat.com

Novavax (NVAX) Rises Higher Than Market: Key Facts

July 14, 2025 | zacks.com

BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT

July 13, 2025 | insidermonkey.com

13 Cheap Stocks with Huge Upside Potential

July 12, 2025 | insidermonkey.com

Novavax, Inc. (NASDAQ:NVAX) Given Average Recommendation of "Hold" by Brokerages

July 12, 2025 | marketbeat.com

Despite Revenue Jump, Novavax Appears Immune To Long-Term Growth

July 11, 2025 | seekingalpha.com

2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet

July 11, 2025 | fool.com

Citi Initiates Coverage of Novavax (NVAX) With a Sell Rating

July 10, 2025 | insidermonkey.com

Novavax (NASDAQ:NVAX) Trading 7.7% Higher - Here's What Happened

July 8, 2025 | marketbeat.com

Vontobel Holding Ltd. Lowers Position in Novavax, Inc. (NASDAQ:NVAX)

July 8, 2025 | marketbeat.com

Novavax Inc. Research & Ratings | NVAX - Barron's

July 6, 2025 | barrons.com

Novavax, Inc. (NVAX) Latest Stock News & Headlines - Yahoo Finance

July 3, 2025 | finance.yahoo.com

RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval

July 3, 2025 | benzinga.com

RFK Jr.‘s top FDA vaccine official restricts 2 COVID vaccine approvals against advice of agency scientists

July 3, 2025 | fortune.com

Moderna’s Shares Gain in Premarket as New Flu Shot Shows Promising Results

July 1, 2025 | tokenist.comT

Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?

July 1, 2025 | zacks.com

Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade

June 27, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HLVX, FDMT, ALEC, and NVAX Company Descriptions

Alector NASDAQ:ALEC

$1.64 +0.05 (+2.83%)

As of 11:40 AM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

4D Molecular Therapeutics NASDAQ:FDMT

$4.21 -0.01 (-0.33%)

As of 11:41 AM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

HilleVax NASDAQ:HLVX

$2.04 -0.02 (-0.97%)

As of 11:34 AM Eastern

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Novavax NASDAQ:NVAX

$7.02 +0.03 (+0.36%)

As of 11:40 AM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time